If confirmed by the EU’s executive commission, the Novavax shot will become the fifth option for Europeans looking to get the jab.
The European Union’s drug regulator approved the Novavax Covid-19 vaccine— long hyped as a highly effective alternative to the mRNA vaccines—for use in adults in the 27-nation bloc on Monday, a major step forward for a fifth coronavirus shot cleared to use in the region as the omicron variant spreads worldwide. After the EMA grants authorization, the executive commission makes the final decision to confirm the vaccine for use. Novavax said the executive commission decision is expected “imminently,” and expects to start shipping vaccines to members of the European Union in January, Reuters reports.
